Bristol-myers Squibb

This study tests whether adding immunotherapy drugs (nivolumab with or without BMS-986205) to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. About 855 adults who are eligi…

This study tests an experimental drug (BMS-986278) in about 1057 adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. The goal is to see if the drug can slow disease progression and is safe. Participants will receive either the drug or a …

This study tests the safety and effectiveness of luspatercept in 85 adults with anemia due to myelodysplastic syndromes (MDS) or beta-thalassemia who need regular red blood cell transfusions. The goal is to see if the drug can reduce the number of transfusions needed. Participant…

This early-stage study tests a new drug combination (BMS-986489) in 10 Chinese adults with small cell lung cancer that has returned or stopped responding to treatment. The main goals are to check safety and how the drug moves through the body, while also looking for signs that it…

This study tests an experimental drug called deucravacitinib for people with lupus that causes skin rashes (discoid or subacute cutaneous lupus). About 74 adults whose rashes are not well controlled by standard treatments will receive either the drug or a placebo. The main goal i…

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colorectal, pancreatic, stomach, and head/neck cancers. The main goals are to check safety and find the right dose. About 213 adults …

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before and after surgery can help people with early-stage (stage II to IIIB) non-small cell lung cancer live longer without the cancer coming back. About 461 participants will receive either…

This study tests whether a new drug called luspatercept works better than a standard drug (epoetin alfa) for treating anemia in adults with a certain type of bone marrow disorder (lower-risk MDS). Participants have not needed blood transfusions or prior anemia treatments. The goa…

This study tests whether adding a new drug (relatlimab) to standard immunotherapy (nivolumab) and chemotherapy works better than nivolumab plus chemotherapy alone for people with advanced or recurrent non-small cell lung cancer. About 468 participants will receive one of the two …

This study tests a new drug, afimetoran, to see if it can safely control active lupus better than a placebo. About 268 adults with lupus will take either the drug or a placebo for 48 weeks. The goal is to reduce lupus symptoms and disease activity, with an option for placebo pati…

This study tests whether deucravacitinib, a daily pill, can reduce disease activity and symptoms in adults with active Sjögren's syndrome. About 774 participants will receive either one of two doses of the drug or a placebo for 52 weeks. The goal is to see if the drug improves gl…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) or adding nivolumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 1,300 participants who have not had prior treatment for inoperable or metastatic urothel…

This study tests two different dosing schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy, in people with advanced or recurrent non-small cell lung cancer who have not had prior treatme…

This study tests whether adding a new drug called relatlimab to the standard immunotherapy nivolumab helps people with advanced melanoma (skin cancer that has spread or cannot be removed by surgery) live longer without their cancer growing. About 714 participants who have not had…

This study is testing a new drug called Golcadomide (BMS-986369) in 85 people in Japan whose T-cell lymphoma has returned or stopped responding to treatment. The goal is to see if the drug is safe, tolerable, and effective at shrinking tumors. The study has two phases: first chec…

This study looks at the long-term safety and effectiveness of the drug deucravacitinib for people with moderate-to-severe plaque psoriasis. Participants had already been in earlier studies of this drug. The study also checks how well the drug works with certain vaccines. About 1,…

This study tests whether the immunotherapy drug nivolumab can delay or prevent liver cancer from returning in patients who have already had surgery or ablation to remove their tumors. About 545 participants at high risk of recurrence will receive either nivolumab or a placebo. Th…

This study tests an oral medication (azacitidine) as maintenance therapy for Chinese adults with acute myeloid leukemia who are in complete remission after chemotherapy. The goal is to see if the drug can help keep the cancer from returning longer than best supportive care alone.…

This study is testing a drug called mavacamten in 50 adults in India who have a condition where the heart muscle is too thick, making it hard for the heart to pump blood. The goal is to see if the drug is safe and can improve symptoms like chest pain and shortness of breath. Part…

This study compares two immunotherapy drugs (nivolumab alone or with ipilimumab) against standard chemotherapy in people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see which treatment better delays cancer growth and improves survival. About 83…

This study looks at how well the drug deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. Researchers will track 153 participants to see if their skin clears up and how much it improves. The goal is to understand the drug's real-…

This study tests whether the immunotherapy drug nivolumab, given after complete surgical removal of stage IIB/C melanoma, can delay or prevent the cancer from coming back. About 790 adults and children who are at high risk for recurrence but have no current signs of disease will …

This study follows 550 adults in Germany with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will check how well the drug clears skin and improves quality of life over 5 years in routine medical practice. The goal is to see if resu…

This study tests a new drug called BMS-986158, alone or with standard treatments (ruxolitinib or fedratinib), in people with intermediate or high-risk myelofibrosis, a serious blood cancer. About 216 adults will take part to see if the drug is safe and helps shrink the spleen or …

This study tests whether the drug deucravacitinib can safely control symptoms of moderate-to-severe systemic lupus erythematosus (SLE) better than a placebo. About 513 adults with active lupus will take either the drug or a dummy pill for several months. The main goal is to see i…

This study looks at how well and how safely the drug ONUREG (oral azacitidine) works in Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants take ONUREG as a maintenance therapy to help prevent the cancer from comin…

This study tests whether the immunotherapy drug nivolumab can help prevent bladder cancer from coming back after surgery. About 700 people who had their bladder removed due to high-risk invasive cancer received either nivolumab or a placebo. The goal is to see if nivolumab extend…

This study tests a new drug, repotrectinib, against the current standard crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 190 participants will be randomly assigned to one of the two pills. The…

This study tests an experimental drug, BMS-986488, given alone or with other treatments, in adults with advanced solid tumors that have not responded to standard therapy. The main goals are to check safety and find the right dose. About 437 participants with specific cancer types…

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard targeted therapy drugs (sorafenib or lenvatinib) for people with advanced liver cancer who haven't had prior treatment. About 732 participants will be enrolled …

This study tests a drug called mavacamten in 44 teenagers (ages 12 to under 18) who have a condition where the heart muscle is too thick and blocks blood flow. The goal is to see if the drug can reduce the blockage and improve symptoms like shortness of breath or chest pain. Part…

This phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to treatment. About 606 participants will be randomly assigned to re…

This study tests if a subcutaneous (under the skin) injection of the drug nivolumab works as well as the standard intravenous (IV) infusion for people with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer. About 681 participants who have already rec…

This study tests whether an oral chemotherapy drug (ONUREG) can help people with low- or intermediate-risk myelodysplastic syndrome (MDS), a blood disorder. About 230 participants will receive either the drug or a placebo, plus standard supportive care. The goal is to see if the …

This study tests a daily pill called deucravacitinib against a placebo in 670 adults with active psoriatic arthritis who have never taken biologic drugs. The goal is to see if the drug reduces joint swelling and pain after 16 weeks, and to check its long-term safety. Participants…

This study tests an experimental drug called BMS-986278 in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing harder over time. About 1,255 adults aged 40 and older with IPF will take either the drug or a placebo to see if it slows…

This study tests an experimental pill called deucravacitinib against a placebo in 516 people with active moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can reduce lupus disease activity better than a dummy pill. Participants must have had lu…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) works better than one drug alone for people with advanced kidney cancer that hasn't been treated before. About 437 participants with intermediate- or poor-risk disease will receive either the co…

This study tests whether an oral chemotherapy drug (azacitidine) can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older who are already in remission. Participants receive either the drug or a placebo along with standard supportive care. T…

This study tests whether starting luspatercept at the highest approved dose can help people with low-risk myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 adults who currently need regular transfusions will receive the drug an…

This study looks at whether the drug mavacamten can improve heart structure in 63 adults with a condition that makes the heart muscle too thick and blocks blood flow. Participants take the medication and have heart scans to measure changes. The goal is to see if the drug can redu…

This study tests the drug fedratinib in about 31 Japanese adults with a bone marrow cancer called myelofibrosis. The goal is to see if it safely shrinks an enlarged spleen and controls the disease. Participants take the drug daily, and doctors monitor side effects and response ov…

This study offers ongoing CC-122 treatment to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor safety and side effects over the long term. It is not a cure, but aims t…

This study looks at whether people with melanoma prefer getting their cancer medicine as a quick shot under the skin or as a longer IV drip. About 100 patients will try both ways and then say which they like better. The goal is to make treatment more convenient and comfortable fo…

This study looks at medical records from about 1,300 adults in Spain with a type of blood cancer called lower-risk myelodysplastic syndromes (MDS) that requires regular blood transfusions. Researchers want to find out how common this condition is, which treatments doctors use fir…

This study follows 800 children with juvenile idiopathic arthritis who are taking abatacept, a medication that calms the immune system. Researchers are tracking serious infections, autoimmune problems, and cancer risks over time to better understand the drug's long-term safety. T…

This study observes 300 adults with advanced non-small cell lung cancer and low PD-L1 levels to see how safe and tolerable their first treatments are. Researchers track side effects, how often they happen, and what healthcare resources are used. The goal is to understand real-wor…

This study follows 200 adults with relapsing-remitting multiple sclerosis (RRMS) who are starting the drug ozanimod for the first time. Researchers want to see how long patients continue taking the medication and how well it works in everyday medical practice. The study does not …

This study was designed to measure how much of the drug ozanimod passes into breast milk and how it might affect breastfed babies. It planned to include lactating women already taking ozanimod for medical reasons. However, the study was withdrawn before enrolling any participants…

This study looks at health records and insurance claims from 6,876 adults with schizophrenia who are taking the medication KarXT. Researchers want to understand who is getting the drug, how it's being prescribed, and whether people stick with it. They will also track hospital vis…

This study follows 208 adults in France with advanced or metastatic stomach, gastroesophageal junction, or esophageal cancer who are receiving nivolumab combined with chemotherapy as their first treatment. The main goal is to see how long patients live in real-world conditions. R…

This study observes 404 adults in Italy with advanced non-small cell lung cancer who are starting treatment with nivolumab plus ipilimumab. Researchers will collect real-world data on how well the treatment works, side effects, and patient characteristics. The goal is to understa…

This study follows over 2,500 people with multiple myeloma to see how well approved treatments work in real-world settings, not just in controlled trials. It includes both newly diagnosed patients and those whose cancer has returned or stopped responding to therapy. The goal is t…

This study watches how doctors treat hypertrophic cardiomyopathy (HCM) in real life, not in a controlled lab. It will follow 331 adults to learn about their symptoms, treatments, and health over time. The goal is to gather information, not to test a new drug or cure.

This study looks back at medical records of children under 18 with advanced melanoma who were treated with the drug ipilimumab. Researchers want to see what serious side effects occurred over time. The goal is to better understand the long-term safety of this treatment in young p…